ArticleFrontiers in immunology2026
Neoadjuvant chemotherapy and immunotherapy followed by radical radiotherapy for locally advanced cervical cancer: efficacy and safety.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the short-term efficacy and safety of neoadjuvant chemoimmunotherapy (NACI) followed by radical radiotherapy (RR) in patients with locally advanced cervical cancer (LACC). Methods: A retrospective analysis was conducted on 60 patients with FIGO 2018 stage IIIA-IVA cervical cancer between June 2022 and July 2024. The experimental group (n=30) received 1-3 cycles of NACI (anti-PD-1/PD-L1 therapy plus platinum-based chemotherapy) followed by RR, which was administered either alone or concurrently with immunotherapy/chemotherapy. The control group (n=30) received RR with or without concurrent chemotherapy. Treatment response was assessed using RECIST 1.1 incorporating gynecological examination. Results: After NACI, the objective response rate (ORR) was 93.3% in the experimental group, increasing to 100% post-radiotherapy. The complete response (CR) rate was comparable between groups (90.0% vs. 86.7%, P = 1.000). With a median follow-up of 20.5 months, the 2-year progression-free survival (PFS) was significantly higher in the experimental group (82.5% vs. 66.0%; HR = 0.364, P = 0.0303), though overall survival (OS) did not differ significantly. The experimental group had a significantly lower incidence of radiotherapy-related intestinal toxicity (20% vs. 60%, P = 0.0033). All immune-related adverse events were grade 1-2. Conclusion: For high-risk LACC, NACI followed by RR was associated with a significantly lower incidence of radiotherapy-related intestinal toxicity. A potential PFS benefit was also observed, although its independent effect could not be confirmed in this limited sample. These findings warrant further investigation in larger prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.